Rurality, Stage-Stratified Use of Treatment Modalities, and Survival of Non-small Cell Lung Cancer.
lung cancer care and outcome disparities
non-small cell lung cancer
rurality
survival
Journal
Chest
ISSN: 1931-3543
Titre abrégé: Chest
Pays: United States
ID NLM: 0231335
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
05
09
2019
revised:
31
03
2020
accepted:
04
04
2020
pubmed:
11
5
2020
medline:
26
5
2021
entrez:
11
5
2020
Statut:
ppublish
Résumé
To eliminate them, non-small cell lung cancer (NSCLC) care and outcome disparities need to be better understood. How does rurality interact with NSCLC care and outcome disparities? We examined guideline-concordant use of active treatment for NSCLC across five institutions in one community-based health care system spanning 44% of the Delta Regional Authority catchment area from 2011 to 2017. Institution- and patient-level rurality were based on Rural-Urban Commuting Area codes. Chi-squared, F-tests, and logistic regressions were used to analyze differences across institutions and rurality; survival was examined using log-rank tests and Cox regression. Of 6,259 patients, 47% resided in rural areas; two of five institutions were rurally located and provided care for 20% of patients. Compared with rural residents at rural institutions, urban and rural residents attending urban institutions were more likely to receive stage-preferred treatment: OR 1.68 (95%CI, 1.44-1.96), and 1.33 (1.11-1.61), respectively, after adjusting for insurance, age, and clinical stage. Urban and rural residents attending urban institutions had a lower hazard of death compared with rural residents attending rural institutions: hazard ratio (HR) 0.69 (0.64-0.75) and 0.61 (0.55-0.67), respectively. Among recipients of stage-preferred treatment, care at urban institutions remained less hazardous: HR 0.7 (0.63-0.79). When further stratified by stage, care for late-stage patients at urban institutions remained less hazardous: HR 0.8 (0.71-0.91). Rurality-associated treatment and survival disparities were present at the patient and institution levels, but the institution-level disparity was greater. Rural residents receiving care at urban institutions had similar outcomes to urban residents receiving care at urban hospitals. To overcome rurality-associated NSCLC survival disparity, interventions should preferentially target the institution level, including expanding access to higher-quality guideline-concordant care.
Sections du résumé
BACKGROUND
To eliminate them, non-small cell lung cancer (NSCLC) care and outcome disparities need to be better understood.
RESEARCH QUESTION
How does rurality interact with NSCLC care and outcome disparities?
STUDY DESIGN AND METHODS
We examined guideline-concordant use of active treatment for NSCLC across five institutions in one community-based health care system spanning 44% of the Delta Regional Authority catchment area from 2011 to 2017. Institution- and patient-level rurality were based on Rural-Urban Commuting Area codes. Chi-squared, F-tests, and logistic regressions were used to analyze differences across institutions and rurality; survival was examined using log-rank tests and Cox regression.
RESULTS
Of 6,259 patients, 47% resided in rural areas; two of five institutions were rurally located and provided care for 20% of patients. Compared with rural residents at rural institutions, urban and rural residents attending urban institutions were more likely to receive stage-preferred treatment: OR 1.68 (95%CI, 1.44-1.96), and 1.33 (1.11-1.61), respectively, after adjusting for insurance, age, and clinical stage. Urban and rural residents attending urban institutions had a lower hazard of death compared with rural residents attending rural institutions: hazard ratio (HR) 0.69 (0.64-0.75) and 0.61 (0.55-0.67), respectively. Among recipients of stage-preferred treatment, care at urban institutions remained less hazardous: HR 0.7 (0.63-0.79). When further stratified by stage, care for late-stage patients at urban institutions remained less hazardous: HR 0.8 (0.71-0.91).
INTERPRETATION
Rurality-associated treatment and survival disparities were present at the patient and institution levels, but the institution-level disparity was greater. Rural residents receiving care at urban institutions had similar outcomes to urban residents receiving care at urban hospitals. To overcome rurality-associated NSCLC survival disparity, interventions should preferentially target the institution level, including expanding access to higher-quality guideline-concordant care.
Identifiants
pubmed: 32387525
pii: S0012-3692(20)30868-0
doi: 10.1016/j.chest.2020.04.042
pmc: PMC7417381
pii:
doi:
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
787-796Subventions
Organisme : NCI NIH HHS
ID : R01 CA172253
Pays : United States
Informations de copyright
Copyright © 2020 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.
Références
Lung Cancer. 2014 Mar;83(3):401-7
pubmed: 24491311
J Clin Oncol. 2006 Jan 20;24(3):332-3
pubmed: 16365176
J Thorac Oncol. 2016 Jun;11(6):880-9
pubmed: 26980472
Thorax. 2015 Feb;70(2):152-60
pubmed: 25074705
J Thorac Oncol. 2012 Dec;7(12):1798-1806
pubmed: 23154551
Ann Am Thorac Soc. 2017 Mar;14(3):403-411
pubmed: 28118039
Chest. 2000 May;117(5):1239-46
pubmed: 10807806
Chest. 2013 May;143(5 Suppl):7S-37S
pubmed: 23649434
Ann Thorac Surg. 2017 Oct;104(4):1161-1170
pubmed: 28709665
Lancet Oncol. 2016 Dec;17(12):1672-1682
pubmed: 27789196
Ann Thorac Surg. 2013 Oct;96(4):1178-1189
pubmed: 23910633
J Clin Oncol. 2004 Aug 15;22(16):3261-8
pubmed: 15310770
J Thorac Oncol. 2019 Dec;14(12):2109-2119
pubmed: 31398540
N Engl J Med. 1999 Oct 14;341(16):1198-205
pubmed: 10519898
JAMA. 2017 Jan 24;317(4):388-406
pubmed: 28118455
J Thorac Oncol. 2016 Jan;11(1):e5-16
pubmed: 26762752
Chest. 2020 Jan;157(1):212-222
pubmed: 31813533
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Cancer. 2018 Sep 15;124(18):3634-3637
pubmed: 30216415
Thorax. 2019 Jan;74(1):51-59
pubmed: 30100577
Cancer. 2018 Sep 15;124(18):3656-3667
pubmed: 30216477
J Thorac Cardiovasc Surg. 2019 Oct;158(4):1220-1229.e2
pubmed: 31147169
JAMA Netw Open. 2018 Aug 3;1(4):e181235
pubmed: 30646114
J Cancer Epidemiol. 2011;2011:107497
pubmed: 22496688
J Thorac Oncol. 2019 Dec;14(12):2053-2061
pubmed: 31195177
J Epidemiol Community Health. 2017 May;71(5):468-474
pubmed: 27913615
Thorax. 2015 Feb;70(2):108-9
pubmed: 25311470
Cancer Epidemiol. 2018 Dec;57:13-23
pubmed: 30268078
Cancer Epidemiol Biomarkers Prev. 2017 Jul;26(7):992-997
pubmed: 28600296